Objective-Thrombin is a multifunctional serine protease that promotes vascular proinflammatory responses whose effect on endothelial MMP-10 expression has not previously been evaluated. Methods and Results-Thrombin induced endothelial MMP-10 mRNA and protein levels, through a protease-activated receptor-1 (PAR-1)-dependent mechanism, in a dose-and time-dependent manner. This effect was mimicked by a PAR-1 agonist peptide (TRAP-1) and antagonized by an anti-PAR-1 blocking antibody. MMP-10 induction was dependent on extracellular regulated kinase1/2 (ERK1/2) and c-jun N-terminal kinase (JNK) pathways. By serial deletion analysis, site-directed mutagenesis and electrophoretic mobility shift assay an AP-1 site in the proximal region of MMP-10 promoter was found to be critical for thrombin-induced MMP-10 transcriptional activity. Thrombin and TRAP-1 upregulated MMP-10 in murine endothelial cells in culture and in vivo in mouse aorta. This effect of thrombin was not observed in PAR-1-deficient mice. Interestingly, circulating MMP-10 levels (PϽ0.01) were augmented in patients with endothelial activation associated with high (disseminated intravascular coagulation) and moderate (previous acute myocardial infarction) systemic thrombin generation. Conclusion-Thrombin induces MMP-10 through a PAR-1-dependent mechanism mediated by ERK1/2, JNK, and AP-1 activation. Endothelial MMP-10 upregulation could be regarded as a new proinflammatory effect of thrombin whose pathological consequences in thrombin-related disorders and plaque stability deserve further investigation. (Arterioscler
T here is growing evidence for an intimate link between inflammatory and coagulation pathways in vascular disease. Inflammation appears to shift the hemostatic mechanisms in favor of thrombosis, and conversely, coagulation pathways influence inflammatory response. [1] [2] [3] Thrombin participates in this interplay and, besides its well established role in thrombosis and hemostasis, activates protease-activated receptors (PARs) and elicits multiple effects in a variety of cell types. 1 PARs have been implicated in the control of vascular tone, vascular permeability, and secretory activity of endothelial cells. 4 -6 In addition, the activation of PARs induces the production of proinflammatory cytokines, upregulates cell adhesion molecules, and promotes leukocyte rolling in different models. [7] [8] [9] PAR-1 seems to be the major mediator of thrombin signaling in vascular endothelial cells (ECs) in mice and humans, and most of the actions of thrombin on ECs have been reproduced using the PAR-1 agonist peptides. 10 Thrombin exerts powerful proinflammatory effects on vascular cells and upregulates some matrix degrading metalloproteinases (MMPs). [11] [12] [13] MMPs are zinc-dependent endopeptidases capable of degrading extracellular matrix (ECM) proteins, but also process a number of bioactive molecules. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine in/activation. MMPs are also thought to play a major role on cell proliferation, migration, differentiation, angiogenesis, apoptosis, and host defense. 14, 15 MMPs also participate in the maintenance of vascular patency after a thrombotic event, which requires fibrin removal by a cooperative proteolytic processing involving plasmin and MMPs. 16 Recently, we demonstrated that MMP-10 is associated with inflammation and subclinical atherosclerosis and is present in atherosclerotic lesions at rupture-prone sites. 17, 18 MMP-10 (stromelysin-2) is a protease that processes various components of basement membrane matrix such as collagen type IV, laminin, and proteoglycans and activates other MMPs (MMP-1, -8, and -13) capable of degrading interstitial components of ECM. 19, 20 However, little is known on its pathophysiological role in thrombotic disorders. In this study we investigated whether human thrombin is able to induce MMP-10 in ECs and in pathological conditions characterized by increased thrombin generation. Our results provide novel insights into the molecular mechanisms underlying vascular effects of thrombin and highlight the potential relevance of MMP-10 in processes associated to local and systemic thrombin generation.
Methods
Detailed explanation of the different experimental procedures is provided as supplementary material (available online at http://atvb.ahajournals.org).
Cell Cultures
Human umbilical vein endothelial cells (HUVECs), human aortic endothelial cells (HAECs), bovine aortic endothelial cells (BAECs), and mouse lung endothelial cells (MLECs) were arrested overnight and stimulated with human thrombin. When needed cells were pretreated for 30 minutes with different inhibitors of signaling pathways.
Real-Time PCR
RNA from cells was extracted and reverse-transcribed. Real-time PCR was performed using TaqMan gene expression assays-ondemand (Applied Biosystems).
MMP-10 Protein Secretion
MMP-10 levels were assayed in conditioned medium by ELISA (R&D Systems). Cell culture and serum samples were diluted 1:5 and 1:2 respectively. The assay recognizes the zymogens and active forms.
Western Blot Analysis
Protein extracts from HUVECs stimulated with thrombin in the presence or in the absence of hirudin and ATAP2 were analyzed by Western blot. Antibodies against ERK1/2 and JNK-1 (either phosphorylated forms of total protein) were used.
MMP-10 Promoter Constructs and Transient Transfection Assays
A 2.0-kb fragment of the human MMP-10 promoter was generated by PCR and cloned into pGL-3 vector (Promega). A series of promoter deletions were generated, and the putative AP-1 site present in MMP-10 promoter was mutated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). HUVECs or BAECs were transfected with the luciferase reporter plasmids and stimulated with thrombin in the presence or absence of inhibitors. Luciferase activity was measured in cell lysates using the Luciferase assay kit (Promega) and a luminometer (Orion I, Berthold Detection Systems). Results were normalized by ␤-galactosidase activity using the Enzyme Assay System (Promega).
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays (EMSAs) were carried out using nuclear extracts from HUVECs stimulated with thrombin in the presence or in the absence of different pathway inhibitors. Doubled stranded probes containing the putative AP-1 element present in MMP-10 were labeled with [␥-32 P]-ATP and T4 polynucleotide kinase and protein-DNA complexes were resolved by electrophoresis.
Induction of MMP-10 by Thrombin in Mouse Aorta: In Vivo Assay
Thrombin (0.1 to 10 U) or TRAP-1 (6 mg/kg) were infused intravenously to wild-type mice (C57Bl/6). PAR-1-deficient (PAR-1 Ϫ/Ϫ ) mice, kindly provided by Dr R. Chambers (University College, London, UK), 21 were also treated with thrombin or saline. MMP-10 in aorta was assessed by real-time PCR and immunohistochemistry. The research was performed in accordance with the European Community guidelines for ethical animal care and use of laboratory animals (Directive 86/609) and was approved by the University of Navarra Animal Research Review Committee.
Circulating MMP-10 Levels in Patients
MMP-10 was measured by ELISA (R&D Systems) in serum from 60 patients with previous acute myocardial infarction (previous AMI) and 12 patients with sepsis-induced disseminated intravascular coagulation (DIC). Another 2 groups of healthy subjects were included, matched for age and sex. Informed consent was obtained from all subjects according to the Declaration of Helsinki.
Statistical Analysis
Continuous variables were expressed as meanϮSD (unless otherwise stated). Differences between groups were assessed by using appropriate statistical tests (SPSS version 11.0). Statistical significance was established as PϽ0.05.
Results

Thrombin Induces MMP-10 mRNA Levels in Human Endothelial Cells
Thrombin increased MMP-10 mRNA levels in HUVECs in a time-and dose-dependent manner ( Figure 1A ). The effect was statistically significant at 2 hours (PϽ0.01) reaching a maximum at 6 hours (PϽ0.01) compared to control, and was prevented by hirudin (a specific thrombin inhibitor). In contrast, no significant changes in TIMP-1 expression could be observed (data not shown). Thrombin also increased MMP-10 protein levels, an effect that was significant (PϽ0.01) 12 hours after stimulation ( Figure 1B) . Similarly, thrombin induced both MMP-10 mRNA and protein levels in adult HAECs, an effect that was prevented by hirudin ( Figure  1C ). In these cells, 0.1 U/mL thrombin promoted a 5-fold increase in MMP-10 mRNA at 12 hours and a 3-fold increase in MMP-10 protein. Actinomycin D blocked thrombininduced MMP-10 upregulation, and no changes in MMP-10 mRNA half-life were observed (data not shown).
PAR-1 Mediates the Upregulation of MMP-10 by Thrombin
PAR-1 blocking antibody ATAP2 completely neutralized thrombin-induced MMP-10 mRNA and protein (Figure 2A ), whereas a control antibody (N-19) did not produce any effect. Moreover, a short peptide agonist for human PAR-1 (TRAP-1) mimicked the effect of thrombin on endothelial MMP-10 expression, whereas a peptide agonist for human PAR-2 (PAR2-AP) had no effect ( Figure 2A ). Taken together, these results indicate that thrombin upregulates endothelial MMP-10 via PAR-1.
MAPK Pathways Are Involved in Thrombin-Induced MMP-10 Gene Expression
Because thrombin activates different signaling pathways in ECs, specific inhibitors were used to address which of these pathways are involved in MMP-10 induction. Results shown in Figure 2B indicate that MMP-10 induction by thrombin was dependent on ERK1/2 (inhibited by PD98059) and JNK (inhibited by SP600125). By contrast, SB203580 (inhibitor of p38 MAPK) and wortmannin (inhibitor of PI3K) did not significantly affect MMP-10 response to thrombin. In the absence of thrombin, inhibitors did not produce any effect on MMP-10 levels (data not shown). Thrombin and TRAP-1 activated ERK1/2 and JNK-1 phosphorylation in a timedependent manner, whereas hirudin and ATAP2 completely prevented thrombin-induced activation of these signaling kinases ( Figure 2C ). Therefore, these results indicate that thrombin upregulates MMP-10 through a PAR-1-dependent mechanism mediated by ERK1/2 and JNK. Unchanged levels of total ERK1/2 (t-ERK1/2) and total JNK-1 (t-JNK-1) are shown.
Involvement of AP-1 in the Induction of MMP-10 by Thrombin
To further characterize the mechanisms underlying MMP-10 upregulation by thrombin we performed transient transfection assays using a luciferase reporter plasmid containing MMP-10 promoter (pMMP10/-1934). In these experiments thrombin (5 U/mL) increased MMP-10 promoter activity more than 2-fold over controls in both HUVECs and BAECs, an effect that was mimicked by TRAP-1 ( Figure 3A ). In addition, ATAP2 but not N19 abrogated the upregulation of MMP-10 promotor activity induced by thrombin in HUVECs. The effect of thrombin was dose-and time-dependent, reaching a maximum 10 hours after thrombin stimulus ( Figure 3B ). Thrombin-induced activity of MMP-10 promoter was prevented by PD98059 and SP600125, but not by SB203580 or wortmannin ( Figure 3C ). To determine the element responsive to thrombin in the MMP-10 promoter, we constructed a series of promoter deletions and examined their activity in transient transfection experiments ( Figure 4A ). The constructs pMMP-10/-1934, -456, -350, and -251 exhibited similar basal promoter activity that was increased by 2-fold after thrombin induction. However, the construct pMMP-10/-47 showed a markedly reduced basal activity with no significant changes after thrombin treatment. . By EMSA we show that thrombin increases the binding to this AP-1 response element in a time-dependent manner. AP-1 binding was verified by antibody supershift assays and was abrogated by site-directed mutagenesis (Figure 4D) . Finally, AP-1 binding to this response element was reduced by PD98059, SP600125, and NDGA, compounds that inhibit ERK1/2, JNK-1, and AP-1, respectively, and reduce thrombin-induced MMP-10 mRNA levels.
Thrombin Induces Vascular MMP-10 Expression In Vivo
Thrombin increased MMP-10 mRNA levels in mouse endothelial cells in a dose-dependent manner ( Figure 5A ). This effect was mimicked by TRAP-1 and was completely prevented by hirudin. MMP-10 mRNA upregulation by thrombin and TRAP-1 was also reduced by PD98059 and SP600125. To determine whether thrombin is able to induce MMP-10 in vivo, we analyzed the expression of MMP-10 in the aorta of mice 6 hours after i.v. administration of thrombin (0.1 to 10 U) or TRAP-1 (6 mg/kg). The expression of MMP-10 in the aorta of saline-treated control mice was undetectable by real-time PCR, but thrombin strongly induced MMP-10 mRNA in a dose-dependent manner ( Figure 5B ). The effect, mimicked by TRAP-1, was observed even at the lowest dose of thrombin administered (0.1 U) and was maximum at the higher dose used (10 U), although the later was associated with a high mortality rate (2 of 4 mice) likely as a result of DIC, as assessed by the presence of diffuse petechial intraabdominal hemorrhage. By contrast, high doses of thrombin were unable to induce MMP-10 mRNA in PAR-1 Ϫ/Ϫ mice. MMP-10 mRNA induction by thrombin was followed by an increase in MMP-10 protein levels. Indeed, immunohistochemical analysis clearly showed the increase of MMP-10 in the intima (endothelial cells and subendothelium) of aortic sections from thrombin-treated animals ( Figure 5C ), indicating that thrombin is able to induce vascular MMP-10 expression in vivo.
Circulating Levels of MMP-10 in Thrombin-Related Clinical Disorders
To further demonstrate whether increased thrombin generation is associated with elevated MMP-10 levels in patholog- ical situations, a small series of patients with well characterized DIC-related sepsis as well as patients with previous AMI were analyzed and compared with age-and sex-matched healthy subjects. Patients with DIC (nϭ12) showed reduced platelet count (139.7Ϯ92.6 ϫ10 9 /L), decreased prothrombin (57.8Ϯ19.7%) and antithrombin activities (35.7Ϯ8.3%), and elevated levels of C-reactive protein (hsCRP) (16.6Ϯ13.0 mg/L) and plasma D-dimer (2044.3Ϯ647.8 ng/mL), indicating an acute inflammatory status associated with systemic thrombin generation and fibrin degradation, typical of overt DIC. MMP-10 levels were significantly higher than in controls (nϭ50) when crude analysis was performed (1682.6Ϯ1713.5 [medianϭ1412.2, IQRϭ1574.3] versus 573.1Ϯ170.0 pg/mL [medianϭ557.9, IQRϭ237.7], PϽ0.05). Further ANCOVA analysis, controlling for age and sex, revealed highly statistically significant differences in MMP-10 levels (1799.1Ϯ237.4 versus 542.7Ϯ116.0 pg/mL, PϽ0.001) between groups ( Figure 6A ). To assess indirectly whether plasmin, which is increased in DIC, could affect MMP-10 activity, in vitro experiments were carried out coincubating rMMP-10 and plasmin. Western blot analysis showed a single band of 45 kDa corresponding to fully activated MMP-10 after plasmin addition, which was corroborated in an MMP-10 activity assay (supplemental Figure I) .
We also measured MMP-10 levels in a group of patients with previous AMI (nϭ60) and enhanced thrombin generation (thrombin peak, 615.5Ϯ26.1 nmol/L versus 497.4Ϯ37.2 nmol/L, PϽ0.01) 22 ( Figure 6B ). MMP-10 levels were increased in these patients as compared to controls (765.3Ϯ 386.7 pg/mL versus 546.12Ϯ119.0 pg/mL, PϽ0.01), which remained statistically significant after adjustment for age and sex (PϽ0.01, Figure 6C ). In patients with previous AMI, MMP-10 positively correlated with inflammatory marker hsCRP (rϭ0.30, PϽ0.05) as well as with the thrombin generation index (rϭ0.31, PϽ0.05) . Finally, as a control of and its prevention by PD and SP is also shown. Data are meanϮSD (nϭ5). B, i.v. thrombin injection induces MMP-10 mRNA levels in the aorta of wild-type mice 6 hours after administration (shaded bars) but had no effect in PAR-1 Ϫ/Ϫ mice (black bars). TRAP-1 (6 mg/kg) elicits a similar response to thrombin. Because after 40 cycles of amplification no expression was detected in vessels from control animals (Control), a reference value of 1 was assigned to these samples. PϽ0.05: * vs controls; † vs 0.1 and 1 U/mL thrombin. C, Immunohistochemistry for MMP-10 in murine aortic sections. MMP-10 immunoreactivity was clearly detected in endothelial cells and subendothelium (arrows) of aortic sections from mice receiving an i.v. injection of 5 U thrombin (right) but not in the arterial wall of control animals (left). L indicates vessel lumen. Control AMI P <0.01 Figure 6 . Circulating levels of MMP-10 are increased in patients with high systemic thrombin generation. A, Circulating MMP-10 levels (pg/mL, meanϮSEM) in patients with disseminated intravascular coagulation (DIC) and controls after adjusting for age and sex. B, Representative thrombogram profiles as assessed by the thrombin generation test in control subjects and patients with previous acute myocardial infarction (AMI). C, Circulating MMP-10 levels (pg/mL, meanϮSEM) in AMI patients and controls.
endothelial activation we show that circulating levels of von Willebrand factor (vWF), a marker of endothelial activation/ injury that has been shown to be induced by thrombin, were increased in patients with either DIC or previous AMI (supplemental Table I ).
Discussion
MMP-10 (stromelysin-2) degrades a broad range of ECM proteins and plays an important role in cancer progression, invasion, and metastasis, liver fibrogenesis, capillary tube regression, wound repair, and maintenance of vascular integrity. [23] [24] [25] [26] Recently, our group reported that CRP induces MMP-10 in human ECs, linking inflammation and proteolysis at cellular level. 17 We also found that circulating MMP-10 levels correlate with systemic inflammatory markers and carotid intima-media thickness (IMT) in apparently healthy subjects. 17, 18 Here we report that thrombin, via PAR-1, markedly enhances expression and secretion of MMP-10 in ECs, both in vitro and in vivo, and that circulating MMP-10 levels are increased in patients with high (DIC) and moderate (previous AMI) systemic thrombin generation. Thrombin is a multifunctional serine protease involved not only in the cleavage of fibrinogen to fibrin and clot formation but also in activating a variety of cell types, including ECs. 27 Thrombin signaling in the endothelium results in a variety of phenotypic changes, including alterations in cell shape, permeability, migration, angiogenesis, and hemostasis. 28 Thrombin selectively enhanced MMP-10 mRNA and protein levels in human ECs, with no changes in TIMP-1 expression. The specificity of the thrombin effect was assessed in vitro by the following experiments: (1) addition of direct thrombin inhibitor hirudin completely blocked the increase of MMP-10 induced by thrombin, (2) the effect was mimicked by a synthetic PAR-1 agonist, and (3) MMP-10 induction was inhibited by a PAR-1 blocking antibody (ATAP2). Therefore, our results show that MMP-10 induction by thrombin requires PAR-1. Because activation of PAR-1 promotes proinflammatory, proangiogenic, and transforming pathways, 29, 30 it might be suggested that MMP-10 could be a mediator of thrombin-induced proinflammatory responses. Finally, under our experimental conditions thrombin was also able to induce MMP-9 mRNA and protein levels (supplemental Figure II) , in agreement with previous data reported in other cell types, 31 emphasizing the potential role of thrombin in vascular remodeling by modulating MMP expression.
Regarding the molecular mechanisms by which thrombin, via PAR-1, leads to endothelial MMP-10 upregulation, our results involve JNK and ERK1/2. The inhibition of thrombininduced MMP-10 mRNA upregulation by actinomycin D indicates that thrombin increases MMP-10 transcription rate. Indeed, in transient transfection experiments thrombin induced the transcriptional activity of a MMP-10 promoter construct, an effect that was prevented by inhibitors of ERK1/2 pathway and JNK. It has been shown that thrombin is able to modulate gene expression in vascular cells by activating a number of transcription factors including AP-1 and CRE binding protein (CREB). 6 In silico analysis of the proximal region of the MMP-10 promoter reveals the presence of putative response elements for several transcription factors, including CREB and AP-1. 15 By mutation deletion analysis and site-directed mutagenesis we identified an AP-1 site that is critical in thrombin-induced MMP-10 expression.
Furthermore, EMSA studies demonstrate that thrombin increases the binding of AP-1 to this site through the activation of ERK1/2 and JNK pathways. Therefore, our results agree with those demonstrating that PAR-1 stimulates ERK1/2 and JNK pathways and activates AP-1, a transcription factor involved in thrombin-induced gene expression associated to different cellular effects triggered by this serine protease, including proinflammatory, proangiogenic, and transforming pathways. 29, 30 We then used a mouse model to study MMP-10 expression in the vascular wall and find out whether thrombin was able to induce MMP-10 after intravenous injection. Thrombin upregulated MMP-10 mRNA levels in the aorta of wild-type mice and increased MMP-10 protein in the subendothelium. In vivo MMP-10 induction was reproduced by TRAP-1 administration but was not observed in PAR-1 Ϫ/Ϫ mice treated with thrombin, further supporting the involvement of PAR-1 and suggesting that MMP-10 could be implicated in processes associated with thrombin generation and ECM degradation in vivo. 3 In this regard, to assess MMP-10 in a clinical setting, circulating MMP-10 levels were measured in patients with thrombin-related disorders, namely sepsisrelated DIC and AMI, both characterized by increased thrombin generation and endothelial activation. 22 Interestingly, we found a 3-fold increase in MMP-10 levels in DIC patients, as compared to age-and sex-matched control subjects. The ability of MMPs to destroy isolated clotting factors and inhibitors suggests that in certain types of DIC direct proteolysis rather than consumption of clotting factors may be operational. 32, 33 Other MMPs, such as MMP-3, the highest one homologous with MMP-10, have been shown to play a role in the regulation of cellular fibrinolysis. 34 In addition, MMP-10 was enhanced in patients with previous AMI and correlated with hsCRP as well as with the thrombin generation index, suggesting that MMP-10 may be a link between systemic inflammation and thrombin generation in atherothrombotic syndromes. 35 In summary, the present findings confirm and extend our previous observations pointing out MMP-10 as a novel biomarker for cardiovascular disorders and show for the first time the molecular mechanisms that connect thrombin with MMP-10, which has recently emerged as a new player in inflammation and vascular integrity. 25, 26, 36 Further studies are needed to establish whether MMP-10 is critical for mediating the effects of thrombin on vascular remodeling, inflammation, or angiogenesis and to define the role of this MMP in the pathophysiology of thrombin-related disorders and plaque stability.
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